Log in

NASDAQ:OPRX - OptimizeRx Stock Price, Forecast & News

$7.57
-0.80 (-9.56 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$7.57
Now: $7.57
$8.37
50-Day Range
$6.71
MA: $8.93
$11.29
52-Week Range
$6.50
Now: $7.57
$17.24
Volume61,638 shs
Average Volume92,461 shs
Market Capitalization$107.30 million
P/E RatioN/A
Dividend YieldN/A
Beta0.43
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems to search, print, or electronically dispense directly to patients, as well as for a network of pharmacies; and Brand and Clinical Messaging that includes various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages targeted by specialty, diagnostic code, and other criteria. The company's products and applications also comprise brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. It also operates Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence, care coordination, and patient engagement; and HIPAA-compliant, an automated and mobile messaging platform that allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. OptimizeRx Corporation is based in Rochester, Michigan.
Read More

Industry, Sector and Symbol

Industry Business services, not elsewhere classified
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:OPRX
CUSIPN/A
CIKN/A
Phone248-651-6568

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.60 million
Cash Flow$0.07 per share
Book Value$1.54 per share

Profitability

Net Income$-3,140,000.00

Miscellaneous

Employees37
Market Cap$107.30 million
Next Earnings Date5/13/2020 (Estimated)
OptionableNot Optionable

Receive OPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.


OptimizeRx (NASDAQ:OPRX) Frequently Asked Questions

How has OptimizeRx's stock been impacted by COVID-19 (Coronavirus)?

OptimizeRx's stock was trading at $7.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OPRX shares have increased by 0.8% and is now trading at $7.57. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of OptimizeRx?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OptimizeRx.

When is OptimizeRx's next earnings date?

OptimizeRx is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for OptimizeRx.

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) issued its quarterly earnings data on Thursday, February, 27th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.02. The company had revenue of $7.38 million for the quarter, compared to analysts' expectations of $7.66 million. OptimizeRx had a negative return on equity of 7.56% and a negative net margin of 12.79%. View OptimizeRx's earnings history.

What price target have analysts set for OPRX?

2 equities research analysts have issued 12 month price objectives for OptimizeRx's shares. Their forecasts range from $20.00 to $20.00. On average, they expect OptimizeRx's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 164.2% from the stock's current price. View analysts' price targets for OptimizeRx.

Has OptimizeRx been receiving favorable news coverage?

Headlines about OPRX stock have been trending extremely positive recently, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OptimizeRx earned a news impact score of 5.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View the latest news aboutOptimizeRx.

Are investors shorting OptimizeRx?

OptimizeRx saw a increase in short interest in March. As of March 13th, there was short interest totaling 916,600 shares, an increase of 11.3% from the February 27th total of 823,200 shares. Based on an average daily trading volume, of 121,900 shares, the short-interest ratio is presently 7.5 days. Approximately 7.8% of the company's shares are short sold. View OptimizeRx's Current Options Chain.

Who are some of OptimizeRx's key competitors?

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital Wireless (IDCC), Bank of Hawaii (BOH), Stag Industrial (STAG), NVIDIA (NVDA), Amgen (AMGN), Verizon Communications (VZ), Etsy (ETSY), Exelixis (EXEL), Sangamo Therapeutics (SGMO) and Alibaba Group (BABA).

Who are OptimizeRx's key executives?

OptimizeRx's management team includes the following people:
  • Mr. William J. Febbo, CEO & Director (Age 50)
  • Ms. Miriam J. Paramore, Pres (Age 56)
  • Mr. Douglas P. Baker, Chief Financial Officer (Age 62)
  • Mr. Terence J. Hamilton, Sr. VP of Sales (Age 54)
  • Mr. James Brooks, Consultant (Age 50)

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by a number of retail and institutional investors. Top institutional investors include P.A.W. Capital Corp (2.01%), State Street Corp (1.69%), Perkins Capital Management Inc. (1.21%), Geode Capital Management LLC (1.18%), Calamos Advisors LLC (1.15%) and Cadence Capital Management LLC (0.97%). Company insiders that own OptimizeRx stock include Awm Investment Company, Inc, Douglas P Baker, Ellen O'connor Vos, Gus D Halas, Miriam J Paramore, Patrick D Spangler and William J Febbo. View institutional ownership trends for OptimizeRx.

Which institutional investors are selling OptimizeRx stock?

OPRX stock was sold by a variety of institutional investors in the last quarter, including 1492 Capital Management LLC, Calamos Advisors LLC, Russell Investments Group Ltd., THB Asset Management, Driehaus Capital Management LLC, Taylor Wealth Management Partners, Cadence Capital Management LLC, and Perkins Capital Management Inc.. View insider buying and selling activity for OptimizeRx.

Which institutional investors are buying OptimizeRx stock?

OPRX stock was acquired by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp, Bullseye Asset Management LLC, Blair William & Co. IL, Atlantic Trust LLC, Rhumbline Advisers, Geode Capital Management LLC, Bank of America Corp DE, and State Street Corp. Company insiders that have bought OptimizeRx stock in the last two years include Ellen O'connor Vos, Gus D Halas, Miriam J Paramore, Patrick D Spangler, and William J Febbo. View insider buying and selling activity for OptimizeRx.

How do I buy shares of OptimizeRx?

Shares of OPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $7.57.

How big of a company is OptimizeRx?

OptimizeRx has a market capitalization of $107.30 million and generates $24.60 million in revenue each year. The company earns $-3,140,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. OptimizeRx employs 37 workers across the globe. View additional information about OptimizeRx.

What is OptimizeRx's official website?

The official website for OptimizeRx is http://www.optimizerx.com/.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company can be reached via phone at 248-651-6568 or via email at [email protected]


MarketBeat Community Rating for OptimizeRx (NASDAQ OPRX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  200
MarketBeat's community ratings are surveys of what our community members think about OptimizeRx and other stocks. Vote "Outperform" if you believe OPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: Market Indexes

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel